Tyr149

Site Information
AHEVGWKyQAVTATL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454781

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	leukemia ( 3 ) , chronic myelogenous leukemia ( 3 ) , liver cancer ( 2 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 1 ) , JHH-4 (hepatic) ( 2 ) , myeloid-bone marrow ( 3 )

References
1	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
2	Tucker M (2009) CST Curation Set: 6390; Year: 2009; Biosample/Treatment: cell line, JHH-4/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Gu T (2006) CST Curation Set: 1408; Year: 2006; Biosample/Treatment: bone marrow, myeloid/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info